NLRP3 and early-onset autosomal dominant Alzheimer disease: Genetic ablation of NLRP3 in Alzheimer’s disease-prone APP-PS1 mice prevents disease progression.164 In the same knock-out model, metabolic and epigenetic alterations associated with glutaminolysis and phagocytotic uptake of amyloid-β can be observed in microglia.165 Τhis effect could be recapitulated through chronic administration of a small molecule NLRP3 inhibitor ex vivo.